Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are major causes of\nacute and chronic liver diseases (e.g. cirrhosis and hepatocellular carcinoma)\nglobally and cause an estimated 1.4 million deaths annually. It is estimated that, at\npresent, 248 million people are living with chronic HBV infection, and that 110 million\npersons are HCV-antibody positive, of which 80 million have active viraemic\ninfection. The burden of chronic HBV and HCV remains disproportionately high in\nlow- and middle-income countries (LMICs), particularly in Asia and Africa. In\nTanzania, the prevalence of HBV ranges from 5.5 - 20% while that of HCV is below\n5%. This was reported in several subpopulation studies in different parts of the\ncountry

Tanzania introduced Hepatitis B Vaccine in 2002, which is routinely offered to infants\nin the National Immunization Program. Despite this notable intervention, the country\nremains with a pool of unvaccinated groups who were born before 2002.\nFurthermore, Hepatitis B vaccinations may be required in certain circumstances such\nas during pilgrimage, international sports, games, travellers and other international\nevents. Also, the HBV vaccination is required to groups such as health workers,\nmilitary and security agencies and long-distance truck drivers who are at a higher\nrisk of exposure due to the nature of their occupations. In addition, HBV vaccination\nis important in key and vulnerable populations to reduce transmission of the disease.

Hepatitis B virus (HBV) and Hepatitis C virus (HCV) infections are major causes of acute and chronic liver diseases (e.g. cirrhosis and hepatocellular carcinoma) globally and cause an estimated 1.4 million deaths annually. It is estimated that, at present, 248 million people are living with chronic HBV infection, and that 110 million persons are HCV-antibody positive, of which 80 million have active viraemic infection. The burden of chronic HBV and HCV remains disproportionately high in low- and middle-income countries (LMICs), particularly in Asia and Africa. In Tanzania, the prevalence of HBV ranges from 5.5 - 20% while that of HCV is below 5%. This was reported in several subpopulation studies in different parts of the country

Tanzania introduced Hepatitis B Vaccine in 2002, which is routinely offered to infants in the National Immunization Program. Despite this notable intervention, the country remains with a pool of unvaccinated groups who were born before 2002. Furthermore, Hepatitis B vaccinations may be required in certain circumstances such as during pilgrimage, international sports, games, travellers and other international events. Also, the HBV vaccination is required to groups such as health workers, military and security agencies and long-distance truck drivers who are at a higher risk of exposure due to the nature of their occupations. In addition, HBV vaccination is important in key and vulnerable populations to reduce transmission of the disease.